SRPT earnings call for the period ending September 30, 2024.
Sarepta Therapeutics: Q3 Earnings Snapshot
These innovative drugmakers have potential catalysts ahead.
These two could become direct competitors relatively soon.
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
Investors in Sarepta Therapeutics, Inc. SRPT need to pay close attention to the stock based on moves in the options market lately. That is because the Oct 18, 2024 $80 Call had some of the highest implied...
Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins.
Both of these biotechs are highly innovative companies.
The S&P 500 Index ($SPX ) (SPY ) Thursday closed up +2.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.76%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +3.06%. US stocks on Thursday...
The S&P 500 Index ($SPX ) (SPY ) today is up +1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.32%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +2.24%. US stocks are trading higher today...